|
Mutation Information
|
Mutation Site
|
R263K |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Combined Mutation
|
in.R263K+in.T66I;in.R263K+in.E157Q+in.T66I;in.R263K+in.S153A;in.R263K+in.Q148R+in.E138K+in.L74M |
|
Genotype/Subtype
|
B;C;AE;AG |
|
Viral Reference
|
AF324493.2;
AF096341.1 |
|
Relevant Drug
|
dolutegravir (DTG);bictegravir (BIC);cabotegravir (CAB);elvitegravir (EVG);raltegravir (RAL) |
|
Country
|
Canada |
Literature Information
|
PubMed PMID
|
30119633
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2018 |
|
Journal
|
Retrovirology |
|
Title
|
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. |
|
Author
|
Oliveira M,Ibanescu RI,Anstett K,Mésplède T,Routy JP,Robbins MA,Brenner BG,Montreal Primary HIV (PHI) Cohort Study Group. |
|
Evidence
|
With EVG, T66I/A, E92G/V/Q, T97A or R263K (n = 16, 3, 2 and 1, respectively) arose by weeks 8-16, followed by 1-4 accessory mutations, conferring high-level resistance (> 100-fold) by week 36.
|
|
|
HIV Mutation Detail Information